Skip to main content

A Novel Protein-Based Anticancer Drug Encapsulating Nanosphere: Apoferritin-Doxorubicin Complex

Buy Article:

$113.00 plus tax (Refund Policy)

Developing a drug delivery system, which is uniform, biocompatible, stable and non-toxic, is a challenging issue in anticancer drug delivery strategies. Ferritin is a nano-size spherical protein with an internal cavity where drug molecules can be encapsulated. The apoferritin-doxorubicin complex has been formed by 'opening' and 'closing' the apoferritin sphere in the presence of doxorubicin. The doxorubicin encapsulation was carried out using direct and step-wise change of pH of the solution from 2.5 to 7.4. Non-denaturing polyacrylamide gels showed that the protein cage of the complex successfully self-assembles into its nanosphere form. It was found that up to 28 molecules of doxorubicin can be capsulated per apoferritin protein and no significant drug leakage occurs during the first two days. The apoferritin-doxorubicin complex is a promising nanocarrier for the delivery of anticancer drugs.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Data/Media
No Metrics

Keywords: CANCER THERAPY; DOXORUBICIN; DRUG DELIVERY; DRUG ENCAPSULATION; FERRITIN; NANOSPHERE

Document Type: Research Article

Publication date: 2012-06-01

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more